Holen Sie sich die Stockscreener-App
8.25
0.86%
0.07
Handel nachbörslich:
8.40
0.15
+1.82%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$8.18
Offen:
$8.31
24-Stunden-Volumen:
4.74M
Relative Volume:
1.57
Marktkapitalisierung:
$586.78M
Einnahmen:
$409.00K
Nettoeinkommen (Verlust:
$-101.35M
KGV:
-5.0613
EPS:
-1.63
Netto-Cashflow:
$-71.49M
1W Leistung:
-8.64%
1M Leistung:
+2.48%
6M Leistung:
+38.89%
1J Leistung:
+3.38%
1-Tages-Spanne:
$8.18
$8.75
1-Wochen-Bereich:
$7.7045
$9.59
52-Wochen-Spanne:
$5.275
$14.84
Altimmune Inc Stock (ALT) Company Profile
Firmenname
Altimmune Inc
Sektor
Branche
Telefon
(240) 654-1450
Adresse
910 CLOPPER ROAD, GAITHERSBURG, MD
Vergleichen Sie ALT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALT
Altimmune Inc
|
8.25 | 586.78M | 409.00K | -101.35M | -71.49M | -1.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Altimmune Inc Stock (ALT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-12 | Eingeleitet | UBS | Buy |
| 2024-04-29 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-01-24 | Eingeleitet | Goldman | Neutral |
| 2023-03-22 | Herabstufung | Goldman | Buy → Neutral |
| 2022-12-01 | Eingeleitet | Goldman | Buy |
| 2021-12-29 | Fortgesetzt | Jefferies | Buy |
| 2021-06-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-02-11 | Eingeleitet | Guggenheim | Buy |
| 2020-12-14 | Eingeleitet | Jefferies | Buy |
| 2020-11-12 | Bestätigt | B. Riley Securities | Buy |
| 2020-09-25 | Eingeleitet | B. Riley FBR | Buy |
| 2020-08-14 | Eingeleitet | Evercore ISI | Outperform |
| 2020-07-31 | Eingeleitet | Piper Sandler | Overweight |
| 2020-07-28 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2020-02-24 | Fortgesetzt | ROTH Capital | Buy |
| 2019-07-19 | Eingeleitet | ROTH Capital | Buy |
| 2017-10-09 | Eingeleitet | Piper Jaffray | Overweight |
Alle ansehen
Altimmune Inc Aktie (ALT) Neueste Nachrichten
Altimmune’s Nasdaq Biotech Index Addition Fuels Retail Enthusiasm, Stock Rebounds - MSN
Altimmune (ALT) Gains on Nasdaq Biotechnology Index Inclusion - GuruFocus.com
Why Altimmune Was Such a Robustly Healthy Stock on Thursday - MSN
Altimmune (NASDAQ:ALT) Trading 4.7% HigherTime to Buy? - MarketBeat
Altimmune joins Nasdaq Biotechnology Index - Investing.com
Altimmune Joins Nasdaq Biotechnology Index, Gears Up for Pivotal MASH Drug Trial Data in 2025 - StockTitan
(ALT) Trading Report - Stock Traders Daily
Altimmune (NASDAQ:ALT) Stock Price Down 5.1%Should You Sell? - MarketBeat
Altimmune's SWOT analysis: pemvidutide's potential reshapes obesity stock outlook - Investing.com
Biodefense Market CAGR of 7.3% Size, Growth Drivers and Forecast 2024-2031 | XOMA corporation, Altimmune Inc., - EIN News
Altimmune 2025: Redefining Obesity And MASH Treatment (NASDAQ:ALT) - Seeking Alpha
Virtu Financial LLC Makes New $674,000 Investment in Altimmune, Inc. (NASDAQ:ALT) - MarketBeat
Altimmune (NASDAQ:ALT) Shares Up 4.9%Still a Buy? - MarketBeat
Altimmune, Inc. (NASDAQ:ALT) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Altimmune reports positive trial results for liver disease drug By Investing.com - Investing.com Nigeria
Altimmune reports positive trial results for liver disease drug - Investing.com India
Trend Tracker for (ALT) - Stock Traders Daily
Altimmune Stock Up More Than 25% in a Month: Here's Why - MSN
Portolan Capital Management LLC Sells 579,266 Shares of Altimmune, Inc. (NASDAQ:ALT) - MarketBeat
Altimmune's SWOT analysis: pemvidutide's potential reshapes obesity and NASH stock outlook By Investing.com - Investing.com South Africa
Altimmune's SWOT analysis: pemvidutide's potential reshapes obesity and NASH stock outlook - Investing.com Canada
Looking At Altimmune's Recent Unusual Options Activity - Benzinga
Altimmune shares surge on CEO's CNBC appearance By Investing.com - Investing.com Canada
Pure Storage Posts Upbeat Results, Joins Cross Country Healthcare, Marvell Technology, Stoke Therapeutics And Other Big Stocks Moving Higher On WednesdayAltimmune (NASDAQ:ALT), Bitdeer Technologies (NASDAQ:BTDR) - Benzinga
Altimmune CEO on what’s next for its experimental obesity drug - CNBC
Altimmune Stock Up More Than 25% In A Month: Here's Why - Barchart
Altimmune to Present at the Cachexia Regulatory & Trials Update Workshop of the 17th International Conference of the Society on Sarcopenia, Cachexia & Wasting Disorders - The Manila Times
Altimmune CMO to Present Key Obesity Drug Data at Major Medical Conference - StockTitan
Altimmune, Inc. (NASDAQ:ALT) Stake Lifted by Bellevue Group AG - MarketBeat
How To Trade (ALT) - Stock Traders Daily
Altimmune to Participate at Two Upcoming Investor Conferences - The Manila Times
Altimmune to Present at Evercore and Piper Sandler Healthcare Conferences in December | ALT Stock News - StockTitan
Altimmune (ALT) Price Target Increased by 16.42% to 22.73 - MSN
Do Redditors Think That Altimmune Inc. (ALT) Has a Big Upside Potential? - Insider Monkey
11 Reddit Stocks with Biggest Upside Potential - Insider Monkey
FY2024 EPS Estimates for Altimmune Reduced by HC Wainwright - MarketBeat
Altimmune, Inc. (NASDAQ:ALT) Receives $20.00 Consensus Target Price from Analysts - MarketBeat
Altimmune, Inc. Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease at The Liver Meeting 2024 - Marketscreener.com
Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting® 2024 - The Manila Times
What is B. Riley's Forecast for Altimmune FY2024 Earnings? - MarketBeat
Altimmune's Pemvidutide Shows 68.5% Liver Fat Reduction in Phase 1b Trial Results - StockTitan
AMERIPRISE FINANCIAL INC's Strategic Acquisition in Altimmune Inc - GuruFocus.com
B. Riley Weighs in on Altimmune's Q1 Earnings (NASDAQ:ALT) - MarketBeat
Altimmune (NASDAQ:ALT) Given Buy Rating at HC Wainwright - MarketBeat
Altimmune Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Finanzdaten der Altimmune Inc-Aktie (ALT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Altimmune Inc-Aktie (ALT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Drutz David | Director |
Aug 19 '24 |
Sale |
6.90 |
16,011 |
110,547 |
41,958 |
| Roberts M Scot | Chief Scientific Officer |
Feb 02 '24 |
Option Exercise |
0.00 |
7,775 |
0 |
44,990 |
| Roberts M Scot | Chief Scientific Officer |
Feb 01 '24 |
Option Exercise |
0.00 |
6,166 |
0 |
39,016 |
| Harris Matthew Scott | Chief Medical Officer |
Feb 02 '24 |
Option Exercise |
0.00 |
7,775 |
0 |
55,965 |
| Harris Matthew Scott | Chief Medical Officer |
Feb 01 '24 |
Option Exercise |
0.00 |
6,166 |
0 |
49,991 |
| Garg Vipin K | President and CEO |
Feb 02 '24 |
Option Exercise |
0.00 |
18,950 |
0 |
300,404 |
| Garg Vipin K | President and CEO |
Feb 01 '24 |
Option Exercise |
0.00 |
16,545 |
0 |
288,767 |
| Roberts M Scot | Chief Scientific Officer |
Jan 30 '24 |
Option Exercise |
0.00 |
9,275 |
0 |
29,699 |
| Harris Matthew Scott | Chief Medical Officer |
Jan 30 '24 |
Option Exercise |
0.00 |
9,275 |
0 |
43,277 |
| Garg Vipin K | President and CEO |
Jan 30 '24 |
Option Exercise |
0.00 |
26,775 |
0 |
276,030 |
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):